868368-26-7

Upstream product

• 216581-47-4 3-(benzyloxy)-6-methyl-4-oxo-4H-pyran-2-carboxylic acid 
• 216581-77-0 2-Hydroxymethyl-3-benzyloxy-6-methyl-pyran-4(1H)-one 
• 216581-46-3 2-formyl-3-benzyloxy-6-methyl-pyran-4(1H)-one 
• 22639-17-4 2-hydroxymethyl-3-hydroxy-6-methyl-pyran-4(1H)-one 
• 7559-81-1 chlorokojic acid 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 644-46-2 allomaltol 
• 870102-32-2 3-benzyloxy-6-methylpyran-4(1H)-one-2-carboxy-N-(4-phenylbenzylamide) 

Downstream Products

• 870102-36-6 AM-2S 

Relevant academic research and scientific papers

Potent, selective pyrone-based inhibitors of stromelysin-1

In an effort to develop alternatives to hydroxamate-based matrix metalloproteinase inhibitors (MPIs), we have utilized the drug discovery program LUDI enhanced with the structural coordinates of a bioinorganic model complex. This method has yielded the fi

ZINC-BINDING GROUPS FOR METALLOPROTEIN INHIBITORS

The present invention relates to metalloprotein inhibitors comprising: a. an organic backbone molecule (Pep) and at least one zinc binding group (ZBG) covalently attached thereto; or b. at least one ZBG substituted by a side chain that comprises one or more amido and/or amino moieties, wherein the ZBG is of formula (I): wherein the wavy line represents a Pep molecule or a side chain that is an R3 or an R4 group which comprises one or more amido and/or amino moieties, and wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.